|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report - Psoriasis Q2 2011
Medpredict, July 2011, Pages: 155
Psoriasis Thought Leader Panel #20 includes the insights from six internationally recognized psoriasis experts (3 US, 1 Swiss, 1 German, 1 French).
This Panel discusses the following:
1) What are the key unmet needs that warrant payers reimbursing more than $20,000/year for new branded psoriasis/psoriatic arthritis therapies?
2) Will a treatment model structured around induction / maintenance get products within the pharmacoeconomic window?
3) How will the competitive dynamics from related immune diseases affect pricing and commercial viability for new brands for the treatment of psoriasis / psoriatic arthritis?
4) What mechanisms and developmental candidates are most likely to succeed in this environment?
For this report the Panelists offered their insight into competitive dynamics of the following classes of therapeutics for psoriasis and/or psoriatic arthritis:
- Antimetabolites
- IL-6, IL-12, IL-17, IL-20, IL-22, IL-23
- JAK1, JAK2, JAK3, TYK2
- p38
- PDE-4
- protein kinase C
- S1P
- TNF
- TLR-7,9
|
|
|
|
